News and Trends 21 Nov 2017 Can this French Biotech Make it Easier to Rescue People from Hypoglycemia? Adocia’s ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk and Eli Lilly in rescuing severe hypoglycemia. Based in Lyon, France, Adocia develops new formulations to improve the performance of diabetes drugs, including an ultra-rapid insulin to help type 1 diabetics control their blood glucose levels […] November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […] November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 It’s World Diabetes Day! But What is Biotech Doing to Fight the Disease? Diabetes is now a major epidemic, with 425 million people living with the condition. Luckily, biotech is working on ways to stop it in its tracks. Not only is it Antibiotic Awareness Week, but today is World Diabetes Day. This year’s theme draws attention to diabetes in women and the right to live a healthy life. […] November 14, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment A small clinical trial in the Netherlands has found that a fecal transplant from a lean donor can temporarily improve diabetes symptoms in obese men. Research published in Cell Metabolism from the University of Amsterdam has found that a fecal transplant from lean men to obese men can cause a short-term improvement in insulin resistance. This […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2017 Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 18 Aug 2017 Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […] August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2017 Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […] July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2017 French Mobile Diabetes Firm gets €17.5M to Build an Artificial Pancreas Cellnovo has launched a capital increase from top European investors to boost its mobile system for diabetes and complete the development of a fully automated artificial pancreas. Cellnovo is a French medtech company with an all-in-one system to manage diabetes in the market. The company has now announced a capital raise of €17.5M to boost […] July 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2017 Videos: Who won the Refresh Early-Stage Startup Battle? The Bonsai goes to… As you might have read in our recap, we had not one but two startup battles for the last edition of Refresh. Watch the companies’ pitches below! Up first was Cambridge Cancer Genomics, which uses AI to design personalised DNA-based tests to help clinicians to better track their patients’ responses to cancer drugs in order to make […] June 26, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email